Ad
ALDR - Alder BioPharmaceuticals Stock Trading
About | Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)
Not available
Quote | Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)
| Last: | $ |
|---|---|
| Change Percent: | 0.00% |
| Open: | $N/A |
| Close: | $18.88 |
| High: | $N/A |
| Low: | $N/A |
| Volume: | 0 |
| Last Trade Date Time: | 11/28/2019 04:57:55 pm |
News | Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)
-
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
-
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
Message Board Posts | Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)
| Subject | By | Source | When |
|---|---|---|---|
| Hummm :-) | WovenO2 | investorshub | 12/17/2018 4:44:20 PM |
| big volume past few days | Verstappenbull | investorshub | 03/21/2018 9:35:07 PM |
| whats going on here? | Verstappenbull | investorshub | 03/21/2018 9:35:02 PM |
| :-) | WovenO2 | investorshub | 01/23/2018 10:13:20 PM |
| POW POW BOOM | WovenO2 | investorshub | 01/08/2018 1:40:19 PM |
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Ad
-
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
-
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
-
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...